

Erratum

Erratum to “Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive” [Contraception 2009;80:445–51]<sup>☆</sup>

Leena Anttila<sup>a</sup>, Michael Kunz<sup>b</sup>, Joachim Marr<sup>b,\*</sup>

<sup>a</sup>The Family Federation of Finland, Turku Clinic, Turku, FIN-20100, Finland

<sup>b</sup>Global Clinical Development, Women's Healthcare, Bayer Schering Pharma AG, D-13342 Berlin, Germany

In the abovementioned article, incorrect data were included for the drsp 3 mg/EE 20 mcg 24/4 group in Fig. 1A on page 448. The correct data are included in the figure shown here.

The figure now supports the statement that scheduled bleeding intensity tended to be lighter for the drsp 3 mg/EE 20 mcg 24/4 group than for the DSG 150 mcg/EE 20 mcg 21/7 group.

The authors regret any inconvenience or confusion this error may have caused.




Fig. 1. The proportion of subjects with scheduled bleeding (maximum intensity) in Cycles 1–6 in (A) the drsp 3 mg/EE 20 mcg group and (B) the DSG 150 mcg/EE 20 mcg group.

<sup>☆</sup> DOI of original article: doi:10.1016/j.contraception.2009.03.013.

\* Corresponding author. Global Clinical Development Women's Healthcare, Bayer Schering Pharma AG, D-13342 Berlin, Germany. Tel.: +49 (0) 30 468 17617; fax: +49 (0) 30 468 15348.

E-mail address: joachim.marr@bayerhealthcare.com (J. Marr).